A Phase I Study of Oral BGJ398 in Asian Patients With Advanced Solid Tumor Having Alterations of the FGF-R Pathway

Trial Profile

A Phase I Study of Oral BGJ398 in Asian Patients With Advanced Solid Tumor Having Alterations of the FGF-R Pathway

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs Infigratinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 22 Dec 2017 Planned End Date changed from 7 Dec 2017 to 7 Dec 2018.
    • 22 Dec 2017 Planned primary completion date changed from 7 Dec 2017 to 7 Dec 2018.
    • 22 Dec 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top